Interaction between the microtubule inhibitor tubulozole and gamma-irradiation in murine tumors in vivo

Distelmans, W; Ginckel, R. Van; Vanherck, W.; Willebrords, R.; Brabander, M. De; Wouters, Luc; Winkel, P. Van den; Backer, Guy De

doi:10.1016/0360-3016(89)90026-6

Cited by 3 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HP--CD was also effectively used to deliver systemically a sparingly water soluble, redoxbased estradiol-chemical delivery system candidate. [79][80][81][82] Distelmans et al 83 showed that HP--CD was effective in encapsulating the drug erbulozole to test its antitumoral and radioprotective potential, while Tuman et al 84 found that a novel nonsteroidal aromatase inhibitor (R 76713) solubilized by HP--CD was effective in inhibiting the aromatization of exogenous rostenedione to estrone. The 10% HP--CD solution vehicle had no effect on this conversion.…”

Section: Parenteral Applications Of Cyclodextrinsmentioning

confidence: 98%

Pharmaceutical Applications of Cyclodextrins. 2. In Vivo Drug Delivery

Rajewski¹,

Stella²

1996

Journal of Pharmaceutical Sciences

759

374

View full text Add to dashboard Cite

The objective of this Review is to summarize and critique recent findings and applications of both unmodified and modified cyclodextrins for in vivo drug delivery. This review focuses on the use of cyclodextrins for parenteral, oral, ophthalmic, and nasal drug delivery. Other routes including dermal, rectal, and pulmonary delivery are also briefly addressed. This Review primarily focuses on newer findings concerning cyclodextrin derivatives which are likely to receive regulatory acceptance due to improved aqueous solubility and safety profiles as compared to the unmodified cyclodextrins. Many of the applications reviewed involve the use of hydroxypropyl-beta-cyclodextrins (HP-beta-CDs) and sulfobutylether-beta-cyclodextrins (SBE-beta-CDs) which show promise of greater safety while maintaining the ability to form inclusion complexes. The advantages and limitations of HP-beta-CD, SBE-beta-CD, and other cyclodextrins are addressed.

show abstract